Hypercholesterolemia

Description

Praluent® is a human monoclonal antibody that inactivates a specific protein (PCSK9) in the liver. By knocking out the protein, this dramatically reduces LDL cholesterol in the blood stream. It is FDA approved as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL.

Praluent® can be self-administered subcutaneously. The recommended dose for Praluent® is 75 to 150 mg every two weeks.

The most common side effects of PCSK9 inhibitor therapy include injection-site swelling, itching or rash, limb pain, fatigue, muscle pain and eye-related events. Some patients also reported memory problems, runny nose and sneezing, upper respiratory tract infection, flu symptoms and back pain.

Repatha® is a human monoclonal antibody that inactivates a specific protein (PCSK9) in the liver. By knocking out the protein, this dramatically reduces LDL cholesterol in the blood stream. It is FDA approved as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL and as an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia who require additional lowering of LDL.

Repatha® can be self-administered subcutaneously. The recommended dose for Repatha® is 140 mg every 2 weeks or 420 mg every 4 weeks.

The most common side effects of PCSK9 inhibitor therapy include injection-site swelling, itching or rash, limb pain, fatigue, muscle pain and eye-related events. Some patients also reported memory problems, runny nose and sneezing, upper respiratory tract infection, flu symptoms and back pain.